Spravato Depression Treatment
Esketamine Nasal Spray
How does Spravato work?
Spravato (Esketamine) is the only FDA-cleared form of ketamine used for the treatment of treatment-resistant depression (TRD) and major depressive disorder (MDD) with suicidal ideation. It is an easy and convenient treatment conveniently delivered to our comfortable office.
HOW DOES SPRAVATO WORK?
Spravato is an NMDA receptor antagonist, an inotropic glutamate receptor. It interacts with DA receptors to reduce dopamine deficiency in brain circuits involving the hippocampus and other brain nuclei. In addition, it interacts with the AMPA receptor to produce antidepressant effects. However, the precise mechanism of action of Spravato is still being investigated by researchers.
It has empirically shown to be a positive impact on reducing depressive symptoms. It rapidly activates a biochemical pathway associated with synaptic plasticity, the mTOR pathway, by increasing expression of a gene encoding the protein BDNF, which gets the m-TOR pathway going. Hence, activation of this pathway leads to increased number of new synapses in targeted brain regions leading to global restoration of brain synapses, both structurally and functionally, that may have been damaged by a chronically ill brain.
Spravato is covered by most insurance. Contact us now to get started on your path to be depression free with Spravato today.
Spravato (Esketamine Nasal Spray)
Spravato is an NMDA receptor antagonist, an inotropic glutamate receptor. It interacts with DA receptors to reduce dopamine deficiency in brain circuits involving the hippocampus and other brain nuclei. Additionally, it interacts with the AMPA receptor to produce antidepressant effects. Although the precise mechanism of action of Spravato is still being investigated by researchers, it has empirically shown to positively impact reducing depressive symptoms.
Spravato rapidly activates a biochemical pathway associated with synaptic plasticity, the mTOR pathway, by increasing the expression of a gene encoding the protein BDNF, which initiates the m-TOR pathway. Activation of this pathway leads to an increased number of new synapses in targeted brain regions, leading to a global restoration of brain synapses, both structurally and functionally, that may have been damaged by a chronically ill brain.
Spravato is covered by most insurance plans. Contact us now to get started on your path to being depression-free with Spravato today.
